FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2581073516> ?p ?o ?g. }

• W2581073516 abstract "Abstract Abstract 1962 Older age and higher serum creatinine levels have long been considered adverse features for overall survival (OS) and progression-free survival (PFS) in MM. Here we are reporting on these variables and their impact on clinical outcomes with the evolution of TT protocols. Among patients <55yr, median OS was 6.4yr with TT1 with 30% alive at 15yr and 12.2yr with TT2. KM curves for TT2 and TT3 were superimposable and medians have not been reached for TT3. (p<0.0001) (Figure 1). The proportions alive were 30% at 15yr in TT1, 60% at 10yr in TT2, and 80% at 5yr in TT3. Median PFS was 2.7yr with TT1, 6.0yr with TT2, and not reached with TT3; ∼10% remain event-free from 15 to 20 years in TT1, 40% at 10yr in TT2, and almost 60% at 5yr in TT3 (p<0.0001). For the middle age group 55–64yr, 15% are alive at 15yr in TT1, 40% at 10yr in TT2, and 75% at 5yr in TT3 (p=0.006). The corresponding PFS was ∼10% at 15yr with TT1, 25% at 10yr with TT2, and 70% at 5yr with TT3 (p<0.0001). For patients >64yr, median OS was 3.3yr with TT1, 6.5yr with TT2, and not reached with TT3 (p=0.01); 15% are alive at 10yr with TT1, 30% at 10yr with TT2, 70% at 5yr with TT3. PFS was 1.9yr with TT1, 3.8yr with TT2 and not reached with TT3; No patients remain at 16yr with TT1, 30% at 10yr with TT2, and 65% at 5yr with TT3. Within protocols, age effects on OS were most apparent in TT1; with TT2 those <55yr outperformed the 2 older age groups, and no significant age difference was apparent for TT3. As to renal function, creatinine >=2 mg/dL was significantly linked to inferior OS in all 3 trials, with medians of 3.6yr v 6.1yr in TT1, 4.1yr v 9.1yr in TT2, and ∼50% v 75% alive at 5yr in TT3 (p=0.008,p=0.001,p=0.002) (Figure 2). PFS was 2.5yr with TT1 regardless of renal function(p=0.36), 3yr v 4.9yr with TT2 (p=0.002), and ∼40% v 70% at 5yr with TT3 (p<0.0001). Thus, major advances in both OS (p<0.0001) and PFS (p<0.0001) were observed with the transition from TT1 to TT2 to TT3 among patients with creatinine <2 mg/dL, whereas results remained dismal for the more impaired renal function group (OS: p=0.22, PFS: p=0.42). Accounting for all possible interactions between TT trial, age, and creatinine, multivariate logistic regression to predict 4-yr OS and 4-yr PFS showed consistently improved OR for OS with TT3>TT2>TT1 regardless of age groups; 4-yr PFS also benefited from TT3>TT2>TT1, but this was most clearly seen in the 55–64yr age group. Significant interactions with creatinine were not observed but levels >=2mg/dL remained an independent dominant adverse variable (OS: OR=2.31, p<0.0001; PFS: OR=2.11, p<0.0001) (Table 1). In conclusion, treatment advances have been realized in patients with preserved renal function across age groups. The poor outcome in patients with creatinine >=2.0mg/dL may not only reflect host- but also MM-related issues. Delaying more toxic VTD-PACE induction until improvement in renal function with VTD for 1 or 2 cycles may improve clinical outcomes. Figure 1: Overall and Progression-Free Survival by Age and Protocol Figure 1:. Overall and Progression-Free Survival by Age and Protocol Figure 2: Overall and Progression-Free Survival by Creatinine and Protocol Figure 2:. Overall and Progression-Free Survival by Creatinine and Protocol Table 1. Multivariate Logistic Regression on Age, Creatinine and Protocol Stepwise selection was used to determine the best models for 4-year OS and PFS in TT1-3. All 2-way (i.e. TT by Age) and 3-way (i.e. TT by Age by Creatinine) interactions were considered for inclusion in the logistic models. The lack of any significant interactions with Creatinine may be due to the small number of patients enrolled to TT trials with Creatinine >= 2 mg/dL. Endpoint OR Comparison OR (95% CI) p-value 4-year OS TT2 v TT1 0.58 (0.42, 0.81) 0.0013 TT3 v TT2 0.77 (0.59, 1.01) 0.0623 Age 55–64 v Age < 55 1.77 (1.34, 2.34) <.0001 Age >= 65 v Age 55–64 1.25 (0.92, 1.71) 0.1596 Cr >= 2mg/dL 2.31 (1.57, 3.41) <.0001 4-year PFS TT2 v TT1 Age < 55 0.28 (0.18, 0.43) <.0001 TT3 v TT2 Age < 55 0.75 (0.49, 1.15) 0.1881 TT2 v TT1 Age 55–64 0.55 (0.31, 0.99) 0.0463 TT3 v TT2 Age 55–64 0.33 (0.22, 0.51) <.0001 TT2 v TT1 Age >= 65 0.63 (0.25, 1.64) 0.3459 TT3 v TT2 Age >= 65 0.59 (0.36, 0.97) 0.0385 Cr >= 2mg/dL 2.11 (1.41, 3.16) 0.0003 Disclosures: No relevant conflicts of interest to declare." @default.
• W2581073516 created "2017-02-03" @default.
• W2581073516 creator A5000879635 @default.
• W2581073516 creator A5001143023 @default.
• W2581073516 creator A5009378735 @default.
• W2581073516 creator A5030746256 @default.
• W2581073516 creator A5030998813 @default.
• W2581073516 creator A5039551593 @default.
• W2581073516 creator A5040237587 @default.
• W2581073516 creator A5043535723 @default.
• W2581073516 creator A5052077997 @default.
• W2581073516 creator A5090044223 @default.
• W2581073516 date "2012-11-16" @default.
• W2581073516 modified "2023-10-01" @default.
• W2581073516 title "Renal Function Impairment (creatinine>=2mg/dL) Limits Progress Noted with the Transition From Total Therapies TT1 to TT2 to TT3 Across Age Groups" @default.
• W2581073516 doi "https://doi.org/10.1182/blood.v120.21.1962.1962" @default.
• W2581073516 hasPublicationYear "2012" @default.
• W2581073516 type Work @default.
• W2581073516 sameAs 2581073516 @default.
• W2581073516 citedByCount "0" @default.
• W2581073516 crossrefType "journal-article" @default.
• W2581073516 hasAuthorship W2581073516A5000879635 @default.
• W2581073516 hasAuthorship W2581073516A5001143023 @default.
• W2581073516 hasAuthorship W2581073516A5009378735 @default.
• W2581073516 hasAuthorship W2581073516A5030746256 @default.
• W2581073516 hasAuthorship W2581073516A5030998813 @default.
• W2581073516 hasAuthorship W2581073516A5039551593 @default.
• W2581073516 hasAuthorship W2581073516A5040237587 @default.
• W2581073516 hasAuthorship W2581073516A5043535723 @default.
• W2581073516 hasAuthorship W2581073516A5052077997 @default.
• W2581073516 hasAuthorship W2581073516A5090044223 @default.
• W2581073516 hasConcept C126322002 @default.
• W2581073516 hasConcept C159641895 @default.
• W2581073516 hasConcept C197934379 @default.
• W2581073516 hasConcept C2780306776 @default.
• W2581073516 hasConcept C71924100 @default.
• W2581073516 hasConcept C86803240 @default.
• W2581073516 hasConceptScore W2581073516C126322002 @default.
• W2581073516 hasConceptScore W2581073516C159641895 @default.
• W2581073516 hasConceptScore W2581073516C197934379 @default.
• W2581073516 hasConceptScore W2581073516C2780306776 @default.
• W2581073516 hasConceptScore W2581073516C71924100 @default.
• W2581073516 hasConceptScore W2581073516C86803240 @default.
• W2581073516 hasLocation W25810735161 @default.
• W2581073516 hasOpenAccess W2581073516 @default.
• W2581073516 hasPrimaryLocation W25810735161 @default.
• W2581073516 hasRelatedWork W2003316889 @default.
• W2581073516 hasRelatedWork W2006330045 @default.
• W2581073516 hasRelatedWork W2035385681 @default.
• W2581073516 hasRelatedWork W2051240121 @default.
• W2581073516 hasRelatedWork W2057554101 @default.
• W2581073516 hasRelatedWork W2079040883 @default.
• W2581073516 hasRelatedWork W2128216530 @default.
• W2581073516 hasRelatedWork W2139161361 @default.
• W2581073516 hasRelatedWork W2261573467 @default.
• W2581073516 hasRelatedWork W2332486031 @default.
• W2581073516 hasRelatedWork W2381166950 @default.
• W2581073516 hasRelatedWork W2392981941 @default.
• W2581073516 hasRelatedWork W2527855948 @default.
• W2581073516 hasRelatedWork W2553175095 @default.
• W2581073516 hasRelatedWork W2554140616 @default.
• W2581073516 hasRelatedWork W2579404640 @default.
• W2581073516 hasRelatedWork W2594749766 @default.
• W2581073516 hasRelatedWork W3114132451 @default.
• W2581073516 hasRelatedWork W3160653160 @default.
• W2581073516 hasRelatedWork W3148049701 @default.
• W2581073516 isParatext "false" @default.
• W2581073516 isRetracted "false" @default.
• W2581073516 magId "2581073516" @default.
• W2581073516 workType "article" @default.